Pancreatic Neoplasm clinical trials

Explore recruiting pancreatic neoplasm clinical trials.

Recruiting pancreatic neoplasm studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pancreatic Neoplasm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II Multicentric Study of Olaparib in PALB2-related Advanced Pancreatic Cancer (PALBOLA)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

C5721001 - Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Germany, Italy, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Pancreatic Neoplasm trials by city

Pancreatic Neoplasm clinical trials

Recruiting pancreatic neoplasm studies right now

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

AB122 Platform Study

A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy

Also recruiting in Europe

A Phase II Multicentric Study of Olaparib in PALB2-related Advanced Pancreatic Cancer (PALBOLA)

C5721001 - Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Pancreatic Neoplasm trials by city

Other conditions